Loading...
NASDAQ: MTSR
Metsera, Inc.
Healthcare · Biotechnology
Market Cap
$7.43B
52w High
$83.86
52w Low
$12.30
P/E
-23.55
Volume
27.87M
Outstanding Shares
105.38M
Skip DCF
The company is still too young and does not have a stable, multi-year FCFF base. Use EV/Revenue multiples and comparable transactions instead of a DCF.
Annual FCFF History
2
Derived observations
Positive FCFF Years
0
Total positive history
Positive Streak
0
Consecutive years
Latest FCFF
-$203.39M
Historical, not forecast
Decision Tree
Is FCFF positive and has it been for 3+ consecutive years?
no
Latest FCFF is not positive.
Is there enough operating history to anchor a DCF?
no
Only 1 years of public or statement history are available, so multiples are more decision-useful than a DCF here.
Company profile
Metsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases.
CEOChristopher Whitten Bernard
SectorHealthcare
IndustryBiotechnology
Employees93
IPO dateJan 31, 2025
Valuation
Forward P/E—
EV/EBITDA-10.94
Enterprise value$2.39B
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Revenue growth—
Gross margin0%
Operating margin0%
ROE-72.78%▼51.86%vs FY2023
Analyst consensus
RatingBuy
Target price$55.50▼21.28%
3
Buy
1
Hold
0
Sell
⚠ Analyst ratings tend to be lagging indicators — upgrades often follow price gains rather than precede them. Use as one signal among many.
Earnings
Last 3 reported quarters plus the next estimate. Switch into compare mode to inspect one metric year-over-year.
Next report
Mar 25, 2026
View
EPS
Actual vs estimate by quarter
Q2'25
ActualEst.
-$1.03
-$0.85
Q3'25
ActualEst.
-$0.66
-$0.66
Q4'25
ActualEst.
-$1.11
-$0.56
Q1'26
Next Est.
—
Revenue
Actual vs estimate by quarter
Q2'25
ActualEst.
—
—
Q3'25
ActualEst.
—
—
Q4'25
ActualEst.
—
—
Q1'26
Next Est.
—